



**SOLVE
ON.**

Cincinnati Children's Hospital Medical Center and Children's Healthcare of Atlanta Receive 2022 Incyte Ingenuity Awards in Graft-Versus-Host Disease

WILMINGTON, Del. – November 1, 2022 – Incyte announced today that Cincinnati Children's Hospital Medical Center and Children's Healthcare of Atlanta have been chosen as the recipients of the 2022 Incyte Ingenuity Awards in graft-versus-host disease (GVHD). This award program aims to support the GVHD community in the U.S. by funding two novel initiatives that address challenges faced by patients with GVHD, caregivers, and healthcare providers. Applications for the 2022 Incyte Ingenuity Awards were reviewed and evaluated by an independent judging panel consisting of GVHD experts and advocates.

Cincinnati Children's Hospital Medical Center will receive the \$100,000 award for its project, *Addressing the Gaps in Education for Children and Young Adults with Chronic GVHD*. In partnership with the Cincinnati Children's Hospital School Services and Cincinnati Children's Hospital MediaLab for Advanced Improvement Methods, the project aims to evaluate the academic performance of children and young adults with chronic GVHD and generate targeted interventions to address gaps in educational resources. The goal of the project is to create nationally used educational strategies and school intervention plans to help ensure equitable education for children and young adults with chronic GVHD.

Children's Healthcare of Atlanta will receive the \$35,000 award for its project, *A Virtual Rehabilitation Program for Children with Chronic GVHD*. In partnership with the Aflac Cancer and Blood Disorders Center, the focus of this project is to improve the wellness of children with chronic GVHD by providing them with 16 weeks of virtual physical rehabilitation services focused on improving aerobic capacity, musculoskeletal strength and flexibility and quality of life. The goal of the project is to create a nationwide practice for caregivers and other organizations to follow.

"The recipients of this year's Incyte Ingenuity Awards in GVHD have both created innovative initiatives to tackle specific challenges faced by a particularly vulnerable group within the GVHD community – children," said Barry Flannelly, Pharm. D., Executive Vice President and General Manager North America, Incyte. "We are honored to support Cincinnati Children's Hospital Medical Center and Children's Healthcare of Atlanta in advancing these important projects over the next year and look forward to seeing the impact they have on care provided to children with GVHD across the country."

The independent judging panel included the following GVHD experts and advocates: Peggy Burkhard, Executive Director, National Bone Marrow Transplant Link; Meredith Cowden, M.A., LPCC-S, Psychotherapist, LifeStance Health, Inc.; Areej El-Jawahri, M.D., Director, Blood and Marrow Transplant Survivorship Program, Associate Director, Cancer Outcomes Research and Education Program, Director, Digital Health at Massachusetts General Hospital; Miguel-Angel Perales, M.D., Chief, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center; Connie A. Sizemore, PharmD, Clinical Pharmacy



**SOLVE
ON.**

Specialist, Blood and Marrow Stem Cell Transplant, Leukemia and Immunotherapy Program, Northside Hospital Cancer Institute. To uphold the integrity of the judging process, any judge affiliated with an applying organization was precluded from the review of that organization's application.

To read more about these winning initiatives, and for more information about the Incyte Ingenuity Awards in GVHD program, visit <https://www.incyteingenuityawards.com/gvhd/>.

About GVHD

GVHD is a condition that can occur after an allogeneic stem cell transplant (the transfer of stem cells from a donor), where the donated cells initiate an immune response and attack the transplant recipient's organs, leading to significant morbidity and mortality. There are two major forms of GVHD: acute, which generally occurs within 100 days of transplant, and chronic, which generally occurs after 100 days of transplant¹. Both forms can affect multiple organ systems, including the skin, gastrointestinal (digestive) track and liver.

About Incyte

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow [@Incyte](https://twitter.com/Incyte).

###

Contacts:

Jenifer Antonacci
Executive Director, Public Affairs
Tel: +1 302 498 7036
jantonacci@incyte.com

Colby Accola
Manager, Public Affairs
Tel: +1 302 518 8267
caccola@incyte.com

¹Ferrara JL., et al. Graft-versus-host disease. Lancet. 2009;373(9674):1550-1561.